- Sourcews Report
- File
- HTML
- Size
- 25 Ko
- URL response
- 100%
- Source quality
- 75%
- Sourcews Explorer
Cervarix, GSK's cervical cancer vaccine, wins tender for Dutch national immunisation programme
20.11.08 - 12:44 ... source : GlaxoSmithKline
... GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix, was today confirmed by the Netherlands Vaccine Institute (NVI) as the cervical cancer vaccine for the Dutch National Immunisation Programme (NIP). Issued: Thursday 20th November 2008, London UK GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix TM, was today confirmed by the Netherlands Vaccine Institute (NVI) as the cervical cancer vaccine for the Dutch National Immunisation Programme (NIP). GSK will supply Cervarixfor the programme, which aims to vaccinate all 12 year old girls. A catch-up programme for all girls aged 13 to 16 will also start within the first half of 2009, with the aim of reducing the risk of HPV infection and cervical cancer for a broader group of Dutch girls. The National programme for girls aged between 12 and 13 will commence in September 2009. It is estimated that more than 350,000 ...» Next (HTML)
Similar news
91% | 14.10.08 - 22:25 ... source : GlaxoSmithKline
... their families Issued: Tuesday 14 October 2008, London, UK The draft recommendations announced today by NICE in the second technology appraisal consultation document (ACD) suggest that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. "Given ...
90% | 14.10.08 - 13:38 ... source : GlaxoSmithKline US
... their families Issued: Tuesday 14 October 2008, London, UK The draft recommendations announced today by NICE in the second technology appraisal consultation document (ACD) suggest that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. "Given ...
87% | 13.11.08 - 16:04 ... source : Merck
... HPV 6, 11, 16 and 18-Related External Genital Lesions WHITEHOUSE STATION, N.J., Nov. 13, 2008 - GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent ...
85% | 10.11.08 - 17:33 ... source : GlaxoSmithKline US
... NC & Santa Clara, CA GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that the New Drug Application (NDA) for Solzira™ (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) has been ...
85% | 10.11.08 - 16:18 ... source : GlaxoSmithKline
... NC & Santa Clara, CA GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that the New Drug Application (NDA) for Solzira™ (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) has been ...
